Short answer
Protara Therapeutics, Inc. (TARA) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$22M
- −63.6% YoY · −0.1% QoQ
- EPS (diluted)
- −$0.34
- −9.7% YoY · +5.6% QoQ
Source: XBRL data from the Protara Therapeutics, Inc. (TARA) Q3 2026 10-Q on SEC EDGAR. USD.
Protara Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales since inception
- Operating margin not meaningful: operating loss $23.2M vs $14.8M YoY
- R&D highest spend, $16.8M vs $9.6M, led by NMIBC expenses of $6.9M
- Cash and securities $143.1M vs $197.9M at December 31, 2025; operating cash use $55.2M
- ADVANCED-2 enrollment expected complete by end of 2026; interim THRIVE-3 results expected fourth quarter 2026
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Carried-forward risks remain applicable across regulatory, operational, competitive, and financial categories
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protara Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.